Supriya Lifescience Ltd
NSE:SUPRIYA
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/E
Price to Earnings (P/E) ratio shows how much investors pay for each dollar of a company`s earnings. It`s calculated by dividing the company`s market value by its total earnings.
Price to Earnings (P/E) ratio shows how much investors pay for each dollar of a company`s earnings. It`s calculated by dividing the company`s market value by its total earnings.
Valuation Scenarios
If P/E returns to its 3-Year Average (26.8), the stock would be worth ₹616.96 (11% downside from current price).
| Scenario | P/E Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 30.2 | ₹694.9 |
0%
|
| 3-Year Average | 26.8 | ₹616.96 |
-11%
|
| 5-Year Average | 23.9 | ₹549.33 |
-21%
|
| Industry Average | 30.4 | ₹698.81 |
+1%
|
| Country Average | 28.7 | ₹660.79 |
-5%
|
Forward P/E
Today’s price vs future net income
| Today's Market Cap | Net Income | Forward P/E | ||
|---|---|---|---|---|
|
₹53.6B
|
/ |
Jan 2026
₹1.9B
|
= |
|
|
₹53.6B
|
/ |
Mar 2026
₹2B
|
= |
|
|
₹53.6B
|
/ |
Mar 2027
₹2.5B
|
= |
|
|
₹53.6B
|
/ |
Mar 2028
₹3.4B
|
= |
|
Forward P/E shows whether today’s P/E still looks high or low once future net income are taken into account.
Peer Comparison
| Market Cap | P/E | ||||
|---|---|---|---|---|---|
| IN |
|
Supriya Lifescience Ltd
NSE:SUPRIYA
|
55.9B INR | 30.2 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
883B USD | 42.8 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
553.5B USD | 26.3 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
216.3B GBP | 27.6 | |
| CH |
|
Novartis AG
SIX:NOVN
|
221.1B CHF | 20.7 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
270.2B USD | 14.8 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.2T DKK | 12 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
151.8B USD | 19.5 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
122B USD | 17.3 |
Market Distribution
| Min | 0 |
| 30th Percentile | 18.9 |
| Median | 28.7 |
| 70th Percentile | 44.4 |
| Max | 877 228.1 |
Other Multiples
Supriya Lifescience Ltd
Glance View
Supriya Lifescience Ltd. supplies active pharmaceuticals ingredients (“APIs”), with a focus on research and development. The company is headquartered in Mumbai, Maharashtra. The company went IPO on 2021-12-28. The company focuses on products in various therapeutic segments, such as Anti-Histamine, Anti-Allergics, Vitamins, Anesthetics and Anti-Asthmatics. Its manufacturing facilities include delineated areas for quality check (QC); manufacturing areas with multiple clean rooms; engineering and maintenance; warehouse; materials and finished goods stores; in-house microbiological laboratory, and functional waste treatment plant. The company handles chemical reactions, such as Friedel Craft’s Acylation, Claisen Condensation, Grignard Reaction, Mannich Reaction, Ritter Reaction, Eschweiler Clark reaction, Hydrogenation, Chlorination, Bromination, Decyanation, Isocyanation, Ethoxylation, Nitration, Alkylation, Reduction, Oxidation, Etherification, Chlorosulphonation, Phosphorylation, Chiral resolution, Heterocyclic chemistry, Thermal ring expansion and Protection/Deprotection.
